학술논문
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Document Type
Article
Author
Source
In The Lancet 26 August-1 September 2023 402(10403):720-730
Subject
Language
ISSN
0140-6736